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ABSTRACT
Increasing evidence indicates that taste receptors mediate a variety of functions in extra-
oral tissues. The present study investigated the expression of bitter taste receptor TAS2R38 in
human adipocytes, the possible link with genetic background and the role of TAS2R38 in cell
delipidation and lipid accumulation rate in vitro. Subcutaneous (SAT) and visceral (VAT) adipose
tissues were collected in 32 obese and 18 lean subjects. The TAS2R38 gene expression and protein
content were examined in whole tissues, differentiated adipocytes and stroma-vascular fraction
cells (SVF). The P49A SNP of TAS2R38 gene was determined in each collected sample. The effect of
two bitter agonists (6-n-propylthiouracil and quinine) was tested. TAS2R38 mRNA was more
expressed in SAT and VAT of obese than lean subjects and the expression/protein content was
greater in mature adipocytes. The expression levels were not linked to P49A variants.
In in vitro differentiated adipocytes, bitter agonists induced a significant delipidation. Incubation
with 6-n-propylthiouracil induced an inhibition of lipid accumulation rate together with
an increase in TAS2R38 and a decrease in genes involved in adipocyte differentiation. In conclu-
sion, TAS2R38 is more expressed in adipocytes of obese than lean subjects and is involved in
differentiation and delipidation processes.
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Introduction
The sense of taste acts as a nutrient-sensing system and
may be considered a kind of detection system, informing us
of suitability to swallow or reject food. Any alteration of
this system might thus contribute to an excessive energy
intake and weight gain [1]. Taste information are perceived
in the gustatory papillae of the oral cavity by specific taste
receptors for bitter, sweet, and umami, that belong to the
superfamily of G-protein-coupled receptors, and salt and
sour receptors, which are ion-sensing channels [2]. Some
evidence demonstrate that overweight/obese subjects have
a lower sensitivity to all taste stimuli than normal weight
individuals [3,4] suggesting that the higher taste threshold
may be involved in the excessive consumption of food.
This finding, however, has not been shared by other studies
due to the different techniques used and the confounding
factors affecting taste perception (i.e. sex, age, smoking/
drinking habits, experiences, socio-cultural habits and
genetic differences). Thus, it has not been established yet
whether the alterations of taste sensitivity are the cause of
overeating or represent the consequence of incorrect eating
habits established with the progression of obesity [5,6]. The
most common way to evaluate the individual variation in
taste is to assess the ability to taste the bitter compound
6-n-propylthiouracil (PROP). PROP sensitivity is consid-
ered a proxy of general taste ability as it is associated with
the sensitivity to other oro-sensory stimuli [5].
The ability to perceive the bitterness of PROP is
a heritable trait and the gene associated with bitter
PROP perception is TAS2R38 [7]. Three common alle-
lic isoforms of TAS2R38 gene identify super-taster
(PAV/PAV), taster (PAV/AVI) and non-taster subjects
(AVI/AVI) and the first variant site (P49A) explain
large part of the phenotypic variation in PROP percep-
tion [7–10]. However, several data demonstrated that
TAS2R38 gene polymorphisms only partially explain
the variance in bitter perception to which other
non-genetic factors may contribute [11,12].
Over the past decade, it has become evident that
taste receptors are expressed not only in taste buds of
the tongue surface but also in extra gustatory organs
(such as: digestive, respiratory, genitourinary systems,
heart, brain, thyroid, skin, placenta and immune cells)
suggesting that different cell type, outside the oral
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cavity, may use taste receptors [13–15]. The exact role
of TAS2R38 outside the gustatory systems is still
elusive.
The evidence that obese individuals express more
TAS2R38 immunoreactive cells in colonic mucosa
than lean subjects [16] and that in mice the intragastric
administration of bitter chemicals alters food intake
and body weight through ghrelin release [17], support
the hypothesis that taste receptors could be involved in
the regulation of appetite hormones secretion, energy
balance and body weight regulation. Sweet and bitter
taste receptors are expressed in mice adipocytes and
affect adipogenesis, even if in a direction not yet clear
[18–21]. No data are available on the presence and
hypothetical function of TAS2R38 in human adipose
tissue/adipocytes.
We here investigated the expression of TAS2R38 in
human subcutaneous (SAT) and visceral adipose tissue
(VAT) from obese and normal weight individuals and
its relation with the P49A variants. In addition, we
assessed the in vitro effect of two different bitter ago-
nists on lipid metabolism.
Materials and methods
Adipose tissue samples
The Ethics Committee of the IRCCS Istituto
Auxologico Italiano (Milan, Italy) approved the study
(https://www.auxologico.it/ricerca-formazione/comi
tato-etico, approval CE code: 2017_05_16_08) and all
subjects gave their written informed consent after a full
explanation of the study. We collected biopsies of sub-
cutaneous (SAT) and visceral (VAT) adipose tissue
from a total of 50 non-diabetic subjects: 32 obese sub-
jects (20 women, 12 men, age 45.1 ± 10.9 years, BMI
43.1 ± 9.2 kg/m2) who underwent bariatric surgery
procedures (such as sleeve gastrectomy, intestinal by
pass, gastric banding) and 18 normal weight individuals
(11 women and 7 men, age 43.5 ± 14.1 years, BMI 24.2
± 2.3 Kg/m2) free from inflammatory, infective or neo-
plastic diseases submitted to aesthetic plastic surgery
procedures.
DNA and RNA extraction and cDNA synthesis
From each collected biopsy, we isolated DNA and RNA.
The biopsies were homogenized by a mechanical disrup-
tion step using the IKA T10 Ultra Turrax (IKA) with
a lysis step using ultra-high-density Bashing Beads
according to the manufacturer’s instructions (Zymo
research), then total DNA was then extracted with
DNA Blood & Tissue Kit following manufacturer
instructions (Qiagen). The RNA was extracted with
RNeasy mini kit following manufacturer instructions
(Qiagen). The RNase-Free DNase Set (Qiagen) was
used for digestion of possible residual DNA during
RNA purification using RNeasy mini Kits in order to
guarantee a complete DNA removal from RNA samples.
Amounts and quality of the extracted DNA/RNA was
assessed by NanoDropH ND-1000 spectrophotometer
(NanoDrop Technologies). The cDNA was obtained by
reverse-transcription of 500 ng extracted RNA, using the
SuperScript VILO cDNA Synthesis Kit and Master Mix
(Life Technologies).
Real-time quantitative PCR (RTqPCR)
TAS2R38, fatty acid synthase (FASN), peroxisome pro-
liferator-activated receptor gamma (PPARγ) and glu-
cose transporter 4 (GLUT4) gene expression levels were
assessed starting from 10 ng of cDNA by using TaqMan
probes (assay on demand, Applied Biosystems). The
housekeeping gene RPLP0 (human ribosomal protein
LP0) was used for data normalization due to the high
stability of expression. Data were analysed with the SDS
V.3 software (Software Diversified Systems) and the
relative quantification, expressed as arbitrary units
(AU), was calculated using the 2^-ΔΔCt method.
Protein extraction and western blotting
Proteins were extracted in isolated mature adipocytes
(A), in stroma vascular fraction (SVF) cells and in 10
days in vitro differentiated adipocytes (DA). Cell and/or
tissue fragments were homogenized in ice-cold RIPA
buffer with freshly added protease inhibitor cocktail
(Roche), then incubated on ice for 30 min and centri-
fuged at 12,000 x g for 30 min at 4°C. The supernatants
were collected, and total protein concentrations were
quantified using Bovine Serum Albumin standard curve
(Thermo Scientific). A total of 20 µg of extracted pro-
teins were separated and transferred to a nitrocellulose
membrane as previously described [22]. After blocking
with 10% bovine serum albumin (BSA, Sigma) for 1 h,
membranes were incubated overnight in primary anti-
bodies at 4°C. The primary antibody was rabbit poly-
clonal anti-human TAS2R38 (Thermo Fisher scientific,
diluted 1:2,000 with 5% BSA) tested for western blot-
ting applications and mouse monoclonal β-actin anti-
body (Fine Test Biotech Co, Ltd., diluted 1:10,000 with
5% BSA) was used for protein loading control. After
incubation, membranes were exposed to 1:10,000 HRP-
conjugated goat anti-rabbit IgG (H + L) or for β-actin
1:5,000 goat anti-mouse IgM secondary antibodies for
1 h at RT. The signals were quantified by densitometric
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procedures and expressed as arbitrary units (AU) after
normalization on β-actin content. The membranes
were treated for chemiluminescence detection (Novex
ECL, HRP Chemiluminescent Substrate Reagent Kit,
Invitrogen) and after exposure to X-ray films
(Amersham Hyperfilm ECL), the signal obtained was
acquired and analysed by the ImageJ software [23].
TAS2R38 genotyping
The P49A genotype of TAS2R38 gene was analysed in all
samples by restriction fragment length polymorphisms
(RFLP) method, as previously described [24]. A total of
500 ng of extracted DNA was amplified with forward (5ʹ-
CCT TCG TTT CTT GGT GAA TTT TTG GGA TGT
AGT GAA GAG GCGG-3ʹ) and reverse (5ʹ-AGG TTG
GCT TGG TTT GCA ATC ATC-3ʹ) primers for human
TAS2R38 by PCR thermal Cycler (Applied Biosystems).
The amplification step was programmed for 30 cycles as
follows: 94°C for 30 s (Denaturing Step), 64°C for 45
s (Annealing step) and 72°C for 45 s (Extending Step)
before finishing with an extension step of 72°C for 5 min.
Tenmicrolitres of amplified fragment (221bp)was digested
with restriction enzyme HaeIII for 2 h at 37°C, then incu-
bated at 80° for 20ʹ and analysed by gel electrophoresis (4%
agarose) with 1X TAE Buffer. Size markers (100 bp DNA
ladder, BioLabs) were loaded into the far left lane of the gel
to check the fragment sizes. The gel was stained by adding 1
μL of ethidium bromide and ran at 120 V for 45 min and
results were recorded using a transilluminator photograph
(Biodoc TM). The tt homozygote yielded the 221 bp uncut
fragment only (considered as non-taster genotype), the Tt
heterozygote yielded three bands (221, 177 and 44 bp)
(considered as medium taster genotype), while TT homo-
zygote yielded two bands of 177 and 44 bp (considered as
super-taster genotype).
In vitro cell cultures
Fragments of collected SAT/VAT samples were digested
with 1 mg/ml collagenase type II (Sigma) as previously
described [25]. Stromal vascular fraction cells were isolated
by centrifugation and cultured at 37°C in a 5% CO2 incu-
bator with 1:1Ham’s F12/DMEM (Invitrogen) supplemen-
ted with 10% decomplemented Foetal Bovine Serum (FBS)
(Sigma), penicillin, streptomycin and amphotericin
B (Invitrogen). Isolated SVF cells were counted with an
automated Beckmann cell counter Z2 (Beckman) after
dilution in Isoton 4 buffer (Beckman) and then seeded.
When the SVF cells reached the confluence the differentia-
tion was started and continued for 10 days with Stem Pro
medium (Invitrogen) without adding FBS. The culture of
the primary adipose SVF cells was performed following
standard protocols [26]. To assess delipidation, 10 days
differentiated cells (containing intracellular triglycerides)
were starved and then stimulated for 4 h (acute stimulus)
with three different concentrations of bitter receptor ago-
nists: 20, 50, and 100 μMofQuinine (Sigma) and 1, 10, and
20 μMof 6-n-propylthiouracil (PROP) (Sigma). Four hours
Caffeine (Sigma, 20, 50, and 100 μM) stimulus was used as
delipidation control, due to its known strong lipolytic effect
through inhibition of phosphodiesterase, stimulation of β-
adrenergic receptors and increase in cyclic adenosine
monophosphate (AMP) [27]. Quinine, caffeine and PROP
were dissolved in distilled sterile water. The sterile water
volume used as dilution vehicle was added in the respective
untreated controls. For the lipid accumulation rate (=
in vitro adipose differentiation process), SVF cells at con-
fluence were differentiated in Stem Pro medium
(Invitrogen) with or without adding 10 µM PROP for a 10-
day chronic stimulus. In unstimulated cells (controls) the
volume of sterile water used to dilute PROP was added.
Every 2 days, cells were collected for the assessment of the
intracellular lipid content and the RNA extracted for the
TAS2R38, FASN, PPARγ and GLUT4 gene expression
detection by RTqPCR, as previously described. The intra-
cellular lipid content was assessed by Victor 3TM 1420
Multilabel fluorescence counter (Perkin Elmer) using
AdipoRed assay reagent (Lonza) and following manufac-
turer instructions. Data were expressed as arbitrary fluor-
escence units (AFU). Cell viability was assessed by Trypan
Blue Solution 0.4% staining (Gibco, Invitrogen) and
inverted microscope (Carl Zeiss) observation.
Statistical analysis
The statistical analysis was carried out using SPSS software
(IBM Corp. Released 2017. IBM SPSS Statistics for
Windows, Version 25.0. Armonk, NY: IBM Corp) and
GraphPad Prism. Data are expressed as mean±standard
error (SE). Means were compared by one-way ANOVA.
The frequencies of P49A gene variants of TAS2R38 were
compared using the χ-square test. Groupmultiple compar-
isons were made using the one-way ANOVA, two-way
ANOVA or two-way Repeated Measure (RM) ANOVA
followed by Bonferroni post hoc test, as appropriate.
A p-value of <0.05 was considered statistically significant.
Results
Gene expression and protein levels of TAS2R38 in
adipose tissue
The TAS2R38 mRNA was more expressed in whole
SAT and VAT of obese than lean subjects (p < 0.05)
(Figure 1(a)), and was not significantly different
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between sexes in both adipose tissue depots (not
shown). In obese subjects, TAS2R38 gene expression
was greater in the in vitro differentiated adipocytes than
in isolated SVF cells (Figure 1(b)). Protein levels of
TAS2R38 in isolated and in in vitro differentiated adi-
pocytes were 1.6 and 1.7 higher than in SVF cells in
both adipose tissue depots (Figure 1(c)).
Genotype variants and TAS2R38 expression
The P49A variants of TAS2R38 gene were analysed in
a total of 47 adipose tissue samples by RFLP (the analysis
was not suitable in three samples, due to low DNA quality)
(Figure 2 (a)). The frequencies of TT, Tt, and tt were,
respectively, 24%, 48%, and 28%. Taking into account the
small sample size of the considered cohort, there was no
significant difference in the P49A genotypes between nor-
mal weight and obese patients, nor in males/females sub-
jects. The TAS2R38 gene expression was not different
among the three P49A gene variants, both in SAT and
VAT depots of all studied subjects (Figure 2(b)), as well as
in the subset of SAT and VAT samples derived from obese
patients (not shown).
Effect of bitter taste agonists on adipocyte biology
The in vitro differentiated adipocytes were stimulated
with three different concentrations of PROP, quinine
and caffeine (used as delipidation control) for
4 h (acute stimulus). All compounds induced
a significant intracellular delipidation compared to
the respective untreated cells, with a greater effect
in SAT-derived adipocytes (p < 0.05). Differently to
caffeine in SAT adipocytes (p < 0.05, 20 vs 50 and
100 µM stimulation) there were no significant differ-
ences between the lipolytic effect of the three con-
centrations of PROP and quinine used (Figure 3). At
the highest quinine concentration used (100 µM),
there was the greater delipidation rate which was
however associated with a significant cytotoxic effect
(cell death in 30% of quinine stimulated adipocytes)
(Figure 3). The chronic incubation of SVF cells with
10 µM PROP during the 10 days differentiation
decreased the lipid accumulation from the sixth day
onwards reaching the lowest level at day 10 in SAT-
derived adipocytes (Figure 4(a)). The 10 µM PROP-
induced decrease in lipid accumulation was asso-
ciated with the significant increase in TAS2R38
expression (p < 0.05) and the decrease in FASN,
PPARγ, GLUT4 expression in SAT and VAT derived
cells under differentiation (p < 0.05, Figure 4(b)).
Discussion
We demonstrated for the first time that TAS2R38 is
present both at RNA and protein level in human
adipocytes with highest expression levels in the adi-
pose tissue of obese than lean individuals. The
TAS2R38 expression in SAT and VAT is similar
among subjects with the three P49A genotype var-
iants, suggesting that the expression of this bitter
receptor in human adipocytes is not influenced by
this genetic component. This result agrees with what
observed in sino-nasal tissues and tongue papillae
where genotype variants of TAS2R38 did not affect
the mRNA expression of the receptor [14].
Furthermore, we observed that the in vitro stimulation
of the TAS2R38 receptor with a specific agonist
(PROP) modulates fundamental processes of adipo-
cyte metabolism, such as delipidation and lipid accu-
mulation. Interestingly, the PROP-induced decrease in
lipid accumulation up-regulated TAS2R38 expression
and at the same time, negatively affected the expres-
sion of genes involved in the differentiation process
(i.e. FASN, PPARγ and GLUT4). This finding sup-
ports the hypothesis that TAS2R38, like perhaps
other taste receptors here not investigated, can mod-
ulate adipocyte functions. The few data available in
literature on taste receptors in adipose tissue, derive
from studies conducted on mice and murine cell lines
[18–21,28,29]. Previous studies demonstrated that
during adipogenesis, adipocytes overexpress the
sweet taste receptors and that these receptors mediate
the inhibitory effect of artificial sweeteners on adipo-
genesis [20]. Furthermore, mice knockout for sweet
taste receptors and fed on an “obesogenic” diet, accu-
mulate less adipose tissue and composed by smaller
adipocytes compared to wild type mice [28,29]. The
signalling modulation of bitter taste receptor to the
membrane cholesterol content [30] and the demon-
strated interaction between fat (CD36) and bitter-taste
receptors [31] represent additional evidence for a role
of TAS2Rs in lipid stores modulation in adipose cells.
Although the in vivo supplementation with quinine
and caffeine is able to decrease the size of mouse
adipocytes [32], the in vitro effects of quinine in
mice are less clear. It was reported that quinine sti-
mulates adipogenesis through a way partially mediated
by the bitter taste receptor T2R106 [21], but also that
the treatment of pre-adipocytes with quinine
decreased differentiation into mature adipocytes [18].
Our results point to a lypolytic and anti-adipogenic
effect of quinine; however, the significant cytoxic
effect observed with the highest concentration of this
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substance may requires that the appropriate concen-
trations be identified for clinical use with a precise
pharmacologic study. The effect of PROP in promot-
ing the delipidation of differentiated adipocytes and
the inhibition of lipid accumulation during adipocyte
differentiation, suggests that TAS2R38 is involved in
lipid mobilization. It is tempting to speculate that
TAS2R38 may participate in counteracting the nutri-
ents overload to which the adipose cells of obese sub-
jects are frequently exposed.
The overexpression of TAS2R38 in adipocytes of
obese subjects further supports the biological role of
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Figure 1. TAS2R38 mRNA gene expression in whole subcutaneous (SAT) and visceral (VAT) adipose tissue of lean subjects (black bars)
versus obese patients (white bars) (panel a, OB-SAT vs NW-SAT, **p < 0.01 and OB-VAT vs NW-VAT, *p < 0.05). TAS2R38 gene
expression in in vitro differentiated adipocytes (DA) and stroma-vascular fraction cells (SVF) from SAT (white bars, SVF vs DA, *p < 0.05)
and VAT (black bars, SVF vs DA, *p < 0.05) of obese patients (panel b). The gene expression is reported as arbitrary units (AU) and
normalized by gene expression of RPLP0 (housekeeping gene) (panels a–b). TAS2R38 protein quantification in isolated adipocytes (A),
SVF cells and in vitro DA from SAT (white bars) and VAT (black bars) of obese patients by western blotting and densitometric analysis
(Arbitrary Densitometric Units, ADU, A, DA vs SVF, *p < 0.05) (c, upper panel). The TAS2R38 and β-Actin protein immuno-detection in
one representative blot is shown (c, lower panel).
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taste receptors in human adipose tissue. This over-
expression may be a consequence of the adipocyte
hypertrophy that occurs following the expansion of
the adipose tissue or represents a new regulatory
mechanism. In diet-induced obese mice, the oral
administration of a bitter taste receptor ligand
decreases weight, fat mass, inflammatory markers,
increased energy expenditure, and improves glucose
tolerance, insulin sensitivity and lipid profile [33].
These benefits were ascribed to the stimulation of
GLP-1 release by entero-endocrine cells; however,
we could now hypothesize that changes in adipocyte
metabolism might have contributed to the beneficial
effects of bitter taste agonists. The adipose tissue
bitter taste receptors may also be involved in the
benefits induced by the bitter herbal substances,
used for centuries in the traditional Chinese medi-
cine to treat metabolic, hearth and digestive dis-
eases [34].
In conclusion, TAS2R38 bitter taste receptor are
overexpressed in adipocytes of obese individuals and
involved in adipocyte metabolism. This finding
opens an exciting new field in the obesity research.
Further research on hormone-sensitive lipase activ-
ity and free fatty acid/glucose uptake pathways reg-
ulation by bitter agonists will help to understand
whether the stimulation of taste receptors may be
a therapeutic strategy to control the lipid accumula-
tion in adipocytes.
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Figure 3. Delipidation (expressed as % of arbitrary fluorescence units, AFU) in in vitro differentiated adipocytes from subcutaneous
(SAT, black bars) and visceral (VAT, white bars) adipose tissue after stimulation with three different concentrations of PROP, quinine
and caffeine (used as delipidation control). * p < 0.05 and **p < 0.01 vs untreated control (CTR).
12 R. CANCELLO ET AL.
Acknowledgments
Authors thank Prof. Ella Pagliarini and Dr. Cristina
Proserpio (Department of Food, Environmental and
Nutritional Sciences (DeFENS), University of Milan, Milan,
Italy) for providing PROP, quinine and caffeine used for
in vitro stimulation.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This research was funded by Italian Ministry of Health.
0
50000
100000
150000
200000
250000
300000
SVF 2 days 4 days 6 days 8 days 10 days
CTR SAT
10 M PROP SATµ
µ
CTR VAT
10 M PROP VAT
)
UF
A(
noitalu
mucc
A
dipiL
* **
*
a
b
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
F
A
S
N
 
(
f
o
ld
  
c
h
a
n
g
e
 P
R
O
P
/
u
n
t
r
e
a
t
e
d
 C
T
R
)
SVF 2d 4d 6d 8d 10d
*
-0.50
-0.40
-0.30
-0.20
-0.10
0.00
0.10
0.20
0.30
4
T
U
L
G
)
R
T
C
d
e
t
a
e
r
t
n
u
/
P
O
R
P
e
g
n
a
h
c
dl
o
f
(
SVF 2d 4d 6d 8d 10d
**
-0.25
-0.20
-015
-0.10
-0.05
0.00
SVF 2d 4d 6d 8d 10d
P
P
A
R

(
f
o
ld
  
c
h
a
n
g
e
 P
R
O
P
/
u
n
t
r
e
a
t
e
d
 C
T
R
)
*
*
0.0
0.5
1.0
1.5
2.0
2.5
SVF 2d 4d 6d 8d 10d
8
3
R
2
S
A
T
)
R
T
C
d
e
t
a
e
r
t
n
u
/
P
O
R
P
e
g
n
a
h
c
dl
o
f
(
**
*
*
*
*
*
*
*
*
*
**
*
*
*
*
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